JP2009227625A - Phonation improving agent - Google Patents
Phonation improving agent Download PDFInfo
- Publication number
- JP2009227625A JP2009227625A JP2008076905A JP2008076905A JP2009227625A JP 2009227625 A JP2009227625 A JP 2009227625A JP 2008076905 A JP2008076905 A JP 2008076905A JP 2008076905 A JP2008076905 A JP 2008076905A JP 2009227625 A JP2009227625 A JP 2009227625A
- Authority
- JP
- Japan
- Prior art keywords
- voice
- improvement agent
- vitamin
- agent according
- tocotrienol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 230000006872 improvement Effects 0.000 claims abstract description 30
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 15
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 15
- 239000001168 astaxanthin Substances 0.000 claims abstract description 15
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 15
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 15
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229930003802 tocotrienol Natural products 0.000 claims abstract description 13
- 239000011731 tocotrienol Substances 0.000 claims abstract description 13
- 235000019148 tocotrienols Nutrition 0.000 claims abstract description 13
- 229930003779 Vitamin B12 Natural products 0.000 claims description 13
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 13
- 235000019163 vitamin B12 Nutrition 0.000 claims description 13
- 239000011715 vitamin B12 Substances 0.000 claims description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 6
- 235000013824 polyphenols Nutrition 0.000 claims description 6
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 241000241413 Propolis Species 0.000 claims description 5
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019136 lipoic acid Nutrition 0.000 claims description 5
- 229940069949 propolis Drugs 0.000 claims description 5
- 229960002663 thioctic acid Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000010638 cranberry seed oil Substances 0.000 claims description 3
- 230000006870 function Effects 0.000 abstract description 14
- 238000012423 maintenance Methods 0.000 abstract description 8
- 230000001755 vocal effect Effects 0.000 abstract description 5
- 229930003270 Vitamin B Natural products 0.000 abstract description 3
- 235000019156 vitamin B Nutrition 0.000 abstract description 3
- 239000011720 vitamin B Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 230000009471 action Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 4
- -1 plants Natural products 0.000 description 4
- 210000001260 vocal cord Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 150000005690 diesters Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ODADKLYLWWCHNB-UHFFFAOYSA-N 2R-delta-tocotrienol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940064063 alpha tocotrienol Drugs 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- BTNBMQIHCRIGOU-UHFFFAOYSA-N delta-tocotrienol Natural products CC(=CCCC(=CCCC(=CCCOC1(C)CCc2cc(O)cc(C)c2O1)C)C)C BTNBMQIHCRIGOU-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 description 1
- 235000019145 α-tocotrienol Nutrition 0.000 description 1
- 239000011730 α-tocotrienol Substances 0.000 description 1
- 235000019151 β-tocotrienol Nutrition 0.000 description 1
- 239000011723 β-tocotrienol Substances 0.000 description 1
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 description 1
- 235000019150 γ-tocotrienol Nutrition 0.000 description 1
- 239000011722 γ-tocotrienol Substances 0.000 description 1
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 1
- 235000019144 δ-tocotrienol Nutrition 0.000 description 1
- 239000011729 δ-tocotrienol Substances 0.000 description 1
- ODADKLYLWWCHNB-LDYBVBFYSA-N δ-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 ODADKLYLWWCHNB-LDYBVBFYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、発声機能を維持または向上するための発声改善剤に関する。 The present invention relates to a voice improvement agent for maintaining or improving a voice function.
発声機能が様々な要因によって変化することが公知となっている。例えば、加齢、喫煙、疲労等の要因によって、発声可能な音域が狭小化することが知られている。また、１回の吸気で声を発することのできる持続時間（本明細書においては当該時間を発声持続時間という）等もまた、加齢等の要因によって変化する。 It is known that the utterance function varies depending on various factors. For example, it is known that the sound range that can be uttered is narrowed due to factors such as aging, smoking, and fatigue. In addition, the duration of time during which a voice can be produced with one inspiration (in this specification, this time is referred to as the duration of utterance) and the like also vary depending on factors such as aging.
そのため、声楽家などは、発することのできる音域や発声持続時間の長さを維持するために、訓練等のほか、十分な体調管理を行っている。 For this reason, vocalists, etc., perform sufficient physical condition management in addition to training, etc., in order to maintain the range of utterances and the length of utterance duration.
しかしながら、訓練等を行わない者にとっては、例えば以前発することのできた音域の声を発することができなくなる結果、以前歌うことのできた歌を満足に歌うことができない、若しくは曲の音調を変更（曲のキーを下げる、または上げる）しなければならないという問題が生じる。 However, for those who do not perform training etc., for example, as a result of being unable to utter a voice of the range that could be uttered before, it is not possible to sing a song that was previously sung satisfactorily or to change the tone of the song (song The problem arises that the key must be lowered or raised.
また、声楽家等が、自らの体調に日々十分な注意を払っている場合であっても、発声機能の調子を維持し続けることは容易ではない。さらに、当該調子を本番に合わせて好調な状態とすることは、困難な場合が多い。 Moreover, even if a vocalist or the like pays sufficient attention to his / her physical condition every day, it is not easy to maintain the tone of the vocal function. Furthermore, it is often difficult to bring the tone into a favorable state according to the performance.
そのため、発声機能の維持または向上を可能とするための手段が切望されている。
本発明はこのような事情に鑑みてなされたものであり、発声機能の維持または向上を行うことができる発声改善剤を提供することを目的とする。 The present invention has been made in view of such circumstances, and an object thereof is to provide an utterance improving agent capable of maintaining or improving the utterance function.
すなわち、本発明は、発声改善剤であって、アスタキサンチンと、トコトリエノールと、ビタミンB１２とを含有してなることを特徴とする。 That is, the present invention is an utterance improving agent characterized by containing astaxanthin, tocotrienol, and vitamin B12.
ここで、アスタキサンチンが、０．５質量％以上含有されるようにしてもよい。また、トコトリエノールが、３．７質量％以上含有されるようにしてもよい。さらに、ビタミンB１２が、０．００５質量％以上含有されるようにしてもよい。 Here, you may make it contain 0.5 mass% or more of astaxanthin. Moreover, you may make it contain 3.7 mass% or more of tocotrienol. Furthermore, you may make it contain vitamin B12 0.005 mass% or more.
さらにまた、本発明の他の態様として、本発明は、請求項１から９のいずれか１つの発声改善剤を投与することを特徴とする発声改善方法である。 Furthermore, as another aspect of the present invention, the present invention provides a speech improvement method, comprising administering the speech improvement agent according to any one of claims 1 to 9.
アスタキサンチンと、トコトリエノールと、ビタミンB１２とを含有してなる本発明の発声改善剤を服用することにより、発声機能の維持または向上を促進させることができる。 By taking the utterance improving agent of the present invention comprising astaxanthin, tocotrienol, and vitamin B12, the maintenance or improvement of the utterance function can be promoted.
本発明の発声改善剤は、アスタキサンチンと、トコトリエノールと、ビタミンB１２とを発声改善のための有効成分として含有してなる。 The vocalization improving agent of the present invention comprises astaxanthin, tocotrienol, and vitamin B12 as active ingredients for improving vocalization.
ヒトは声帯を使用して発声を行うことが公知となっている。本発明の発明者は、喫煙、空気汚染、乾燥、声帯粘膜の炎症等が発声可能な音域の狭小化に影響を及ぼしている可能性に着眼した。そして、声帯の機能を向上させるための構成について鋭意研究を行った結果、アスタキサンチンと、トコトリエノールと、ビタミンB１２とを組み合わせて投与することにより、発声可能な音域の維持または拡張が可能となることを見出し、これらを含有する本発明の発声改善剤を成すに至った。これらの成分は、声帯粘膜の炎症抑制等に作用していることが考えられ、発声の改善に係るこれらの物質の知見は過去に得られていない。 Humans are known to utter using vocal cords. The inventor of the present invention has focused on the possibility that smoking, air pollution, dryness, inflammation of the vocal fold mucosa, etc. have an effect on the narrowing of the sound range that can be uttered. And as a result of earnestly researching about the structure for improving the function of the vocal cord, it is possible to maintain or expand the vocal range that can be uttered by administering astaxanthin, tocotrienol, and vitamin B12 in combination. It came to make the speech improvement agent of this invention containing the headings and these. These components are considered to act to suppress inflammation of the vocal fold mucosa, and knowledge of these substances relating to improvement in vocalization has not been obtained in the past.
したがって、本発明によれば、発声機能の維持または向上を行うことができる。具体的には、発声可能な音域の維持または拡張を行うことができるほか、発声持続時間もまた、服用前と比較して向上させることができる。さらに、本発明の発声改善剤は、個人差はあるが早い場合で、服用後３０分程度でその効果が現れる。すなわち、具体的に説明すれば、カラオケなどの予定が急に決定した場合でも、本発明の発声改善剤の作用効果を享受することが可能となる。 Therefore, according to the present invention, the utterance function can be maintained or improved. Specifically, it is possible to maintain or expand the range of voices that can be spoken, and to improve the duration of voice production as compared to before taking. Furthermore, the voice improvement agent of the present invention has an individual difference but is early, and the effect appears about 30 minutes after taking. That is, if it demonstrates concretely, even if a schedule, such as karaoke, is decided suddenly, it will become possible to enjoy the effect of the speech improvement agent of this invention.
以下、本実施形態の発声改善剤の構成について詳しく説明する。 Hereinafter, the structure of the voice improvement agent of this embodiment is demonstrated in detail.
アスタキサンチンはサケやイクラなどに含まれる赤色のカロテノイド色素の一種であり、ビタミンEの５００〜１０００倍の強力な抗酸化作用を有する。本発明において用いられるアスタキサンチンとしては、例えば、アスタキサンチンを多く含むヘマトコッカス藻色素を使用することができる。ここで、アスタキサンチンは、抗炎症作用、筋肉疲労抑制作用などが向上することにより、発声機能の維持または向上をより促進させることが可能となるため、本実施形態の発声改善剤あたり０．５質量％以上含有されることが好ましい。なお、本実施形態の発声改善剤に用いられるアスタキサンチンは、遊離体のほか、モノエステル体やジエステル体であってもよい。ジエステル体は２つの水酸基がエステル結合により保護されているため化学的及び物理的に遊離体やモノエステル体よりも安定性が高く本発明の組成物中で酸化分解されにくい。しかし、生体中に取り込まれると生体内酵素により速やかにアスタキサンチンに加水分解され、効果を示すものと考えられている。 Astaxanthin is a kind of red carotenoid pigment contained in salmon, salmon roe, etc., and has a strong antioxidant effect 500 to 1000 times that of vitamin E. As astaxanthin used in the present invention, for example, Haematococcus alga pigment containing a large amount of astaxanthin can be used. Here, astaxanthin improves the anti-inflammatory action, the muscle fatigue suppression action, and the like, thereby making it possible to further promote the maintenance or improvement of the voicing function. Therefore, 0.5 mass per voicing improver of the present embodiment. % Or more is preferable. In addition, the astaxanthin used for the voice improvement agent of this embodiment may be a monoester form or a diester form in addition to the free form. Diesters are chemically and physically more stable than free and monoesters because two hydroxyl groups are protected by ester bonds, and are less susceptible to oxidative degradation in the composition of the present invention. However, it is considered that when it is taken into the living body, it is rapidly hydrolyzed to astaxanthin by an in vivo enzyme and exhibits an effect.
トコトリエノールは、ビタミンＥ（トコフェロール）同族体であり、トコフェロールの直鎖アルキル基に３つの不飽和結合部分を有する化合物であって、ビタミンEの数十倍程度の強い抗酸化作用を有する。また、高脂血症改善作用を有する成分としても知られている。ここで、トコトリエノールは、微小循環改善作用（血行促進）により、発声機能の維持または向上をより促進させることが可能となるため、本実施形態の発声改善剤あたり３．７質量％以上含有されることが好ましい。トコトリエノールは、植物等の天然物の圧搾、抽出、または合成などの方法で得ることができ、一般的にはヤシ科植物の果皮および／または種子から抽出される。本実施形態の発声改善剤においては、天然物由来、合成物のいずれであっても用いることができる。また、α−トコトリエノール、β−トコトリエノール、γ−トコトリエノール、δ−トコトリエノールのいずれを使用することも可能であり、これらを組み合わせて使用してもよい。 Tocotrienol is a vitamin E (tocopherol) homologue, a compound having three unsaturated bonds in the linear alkyl group of tocopherol, and has a strong antioxidative effect about several tens of times that of vitamin E. It is also known as a component having an action for improving hyperlipidemia. Here, the tocotrienol can be further promoted to maintain or improve the vocal function by the microcirculation improving action (promoting blood circulation), and therefore is contained in an amount of 3.7% by mass or more per the voice improving agent of the present embodiment. It is preferable. Tocotrienol can be obtained by a method such as pressing, extraction, or synthesis of natural products such as plants, and is generally extracted from the peels and / or seeds of palm plant. In the voice improvement agent of the present embodiment, any of natural products and synthetic materials can be used. Any of α-tocotrienol, β-tocotrienol, γ-tocotrienol, and δ-tocotrienol can be used, and these may be used in combination.
ビタミンB１２は、ビタミンB群に属するビタミンであり、貧血防止作用のほか、高い神経保護作用を有する。ビタミンB１２としては、例えばシアノコバラミン、メチルコバラミン、アデノシルコバラミンおよびヒドロキシルコバラミンとすることができる。ここで、ビタミンB１２は、特に葉酸との併用による造血作用、口腔粘膜の炎症・潰瘍防御、神経系統機能維持により、発声機能の維持または向上をより促進させることが可能となるため、本実施形態の発声改善剤あたり０．００５質量％以上含有されることが好ましい。 Vitamin B12 is a vitamin belonging to the vitamin B group, and has a high neuroprotective action in addition to an anemia prevention action. As vitamin B12, for example, cyanocobalamin, methylcobalamin, adenosylcobalamin and hydroxylcobalamin can be used. Here, since vitamin B12 can promote the maintenance or improvement of the vocal function more particularly by the hematopoietic action in combination with folic acid, the inflammation / ulcer protection of the oral mucosa, and the maintenance of the nervous system function, this embodiment It is preferable to contain 0.005 mass% or more per voicing improver.
また、本実施形態の発声改善剤は、以下の成分をさらに含有することが好ましい。これらの成分は、活性酸素消去、血管の強化、抗アレルギーなどの作用を有しているものと考えられる。 Moreover, it is preferable that the voice improvement agent of this embodiment further contains the following components. These components are considered to have actions such as scavenging active oxygen, strengthening blood vessels, and antiallergy.
葉酸は、ビタミンB群に属するビタミンであり、ビタミンB１２と協働する赤血球の産生、保護や、タンパク質の代謝あるいは核酸（ＤＮＡやＲＮＡ）の産生、体細胞の分化・増殖、また糖やアミノ酸消費に重要な役割を有する。葉酸は、本実施形態の発声改善剤あたり０．０１９質量％以上含有されることが好ましい。 Folic acid is a vitamin belonging to the vitamin B group. Production and protection of red blood cells in cooperation with vitamin B12, metabolism of proteins or production of nucleic acids (DNA and RNA), differentiation and proliferation of somatic cells, consumption of sugar and amino acids Has an important role. Folic acid is preferably contained in an amount of 0.019% by mass or more per vocalization improving agent of the present embodiment.
プロポリスエキスは、蜜蜂が木の樹液や花の花粉から集めた膠状物質（プロポリス）から抽出された抽出物（エキス）であって、フラボノイドなどのポリフェノールを多く含み、抗菌作用、各種薬理作用を有する。プロポリスエキスは、本実施形態の発声改善剤あたり０．６質量％以上含有されることが好ましい。 Propolis extract is an extract (extract) that is extracted from bee matter collected by bees from tree sap and flower pollen (propolis). It contains a lot of polyphenols such as flavonoids, and has antibacterial and various pharmacological effects. Have. The propolis extract is preferably contained in an amount of 0.6% by mass or more per utterance improving agent of the present embodiment.
α−リポ酸（チオクト酸）は、高い抗酸化作用を有するほか、一度作用して抗酸化作用を失った物質の抗酸化作用を再生するはたらきがあり、より抗酸化力を高めることができると考えられている。また、活性酸素消去作用、体内の有害な金属に配位し、肝臓を守る作用（キレート作用）や、抗肥満作用も知られている。α−リポ酸は、本実施形態の発声改善剤あたり１．０質量％以上含有されることが好ましい。 α-Lipoic acid (thioctic acid) has a high anti-oxidation effect, and also has the function of regenerating the anti-oxidation effect of substances that once acted and lost the anti-oxidation effect, so that the antioxidant power can be further increased. It is considered. Also known are an active oxygen scavenging action, an action to coordinate with harmful metals in the body and protect the liver (chelation action), and an anti-obesity action. α-lipoic acid is preferably contained in an amount of 1.0% by mass or more per voicing improver of the present embodiment.
りんごポリフェノールは、りんごから抽出されたポリフェノール群（エピカテキン、カフェ酸、プロアントシアニジン等）であって、抗酸化作用、脂質代謝向上作用、血圧上昇抑制作用、抗アレルギー作用、抗炎症作用を有する。りんごポリフェノールは、本実施形態の発声改善剤あたり２．７質量％以上含有されることが好ましい。 Apple polyphenol is a group of polyphenols extracted from apple (e.g. epicatechin, caffeic acid, proanthocyanidins, etc.), and has an antioxidant action, an action to improve lipid metabolism, an antihypertensive action, an antiallergic action, and an antiinflammatory action. The apple polyphenol is preferably contained in an amount of 2.7% by mass or more per utterance improving agent of the present embodiment.
クランベリーシードオイルは、クランベリーシードから抽出されたオイル群であって、α−リノレン酸を多く含み、抗炎症作用を有する。 Cranberry seed oil is a group of oils extracted from cranberry seed and contains a large amount of α-linolenic acid and has an anti-inflammatory effect.
このほか、本実施形態の発声改善剤は、質量比で１００とする量のこれら各成分の担体等を含む。担体は、各成分を溶解または分散させて保持する。担体は特に限定されないが、胃腸経路からの各成分の吸収を助けるものであるのが好ましい。適当な担体の例は、食用油(例えばオリーブ油)、動物産物に基づく担体(例えばゼラチン)、アラビアガム、スクロース、脂質、モノおよびジグリセリド、ならびにマルトデキストリンである。また、水も担体として使用することができるが、通常、適当な乳化剤(例えば、レシチン、ソルビタン モノラウレート)とともに使用される。なお、各成分の混合方法は、各成分ができるだけ均一に分散するように混合すればよく、特に限定されない。また、担体のほか、硬度調整剤や吸収改良剤を含むようにしてもよい。 In addition, the voice improvement agent of the present embodiment includes a carrier for each of these components in an amount of 100 by mass ratio. The carrier holds each component dissolved or dispersed. The carrier is not particularly limited, but is preferably one that assists absorption of each component from the gastrointestinal route. Examples of suitable carriers are edible oils (eg olive oil), animal product based carriers (eg gelatin), gum arabic, sucrose, lipids, mono and diglycerides, and maltodextrins. Water can also be used as a carrier, but is usually used together with a suitable emulsifier (for example, lecithin, sorbitan monolaurate). In addition, the mixing method of each component should just mix so that each component may disperse | distribute as uniformly as possible, and is not specifically limited. In addition to the carrier, a hardness adjusting agent or an absorption improving agent may be included.
本実施形態の発声改善剤は、例えば、溶液、オイル、エマルジョン、懸濁液または分散液として、経口投与することができる。適当な担体形態は、例えば、カプセルまたは錠剤である。本実施形態の発声改善剤は、通常、軟ゼラチンカプセルの形態で提供される。 The voice improvement agent of this embodiment can be orally administered, for example, as a solution, oil, emulsion, suspension or dispersion. Suitable carrier forms are, for example, capsules or tablets. The voice improvement agent of this embodiment is usually provided in the form of a soft gelatin capsule.
以下、実施例によって本発明の発声改善剤をより具体的に説明する。なお、本発明はこれに限定されるものではない。 Hereinafter, the utterance improving agent of the present invention will be described more specifically by way of examples. Note that the present invention is not limited to this.
以下に示す成分を混合して本実施例の発声改善剤を製造した。 The following components were mixed to produce the voice improvement agent of this example.
具体的には、ヘマトコッカス藻色素、トコトリエノール、ビタミンB12、葉酸、プロポリスエキス、α−リポ酸、りんごポリフェノール、クランベリーシードオイル、オリーブ油、グリセリン、グリセリンエステル、ミツロウ、結晶セルロースを混合し、ゼラチンカプセルに充填した。 Specifically, hematococcus alga pigment, tocotrienol, vitamin B12, folic acid, propolis extract, α-lipoic acid, apple polyphenol, cranberry seed oil, olive oil, glycerin, glycerin ester, beeswax, crystalline cellulose are mixed and gelatin capsules Filled.
カプセル１粒（４７０ｍｇ）あたり、アスタキサンチン、トコトリエノール、ビタミンB１２等は以下の量で含まれる。 Astaxanthin, tocotrienol, vitamin B12 and the like are contained in the following amounts per capsule (470 mg).
以上の本実施例の発声改善剤を、１日２回食後、１カプセルづつ３０日間、声楽家、歌手（ロック、民謡、長唄、ヨーデル）、アナウンサー、舞台俳優、声優、能役者などを職業とするモニター（１５名）に服用してもらい、官能試験を行った。また、比較例として、服用前の試験結果を用いた。 The above-mentioned voice improvement agent of the present embodiment, after serving twice a day, for 30 days for each capsule, singer, singer (rock, folk song, Nagatoro, Yodel), announcer, stage actor, voice actor, noh actor, etc. A monitor (15 persons) took the sensory test. Moreover, the test result before taking was used as a comparative example.
まず、モニターの発声可能な音域について試験を行った。試験結果を表２および表３に示す。表２および表３において、音名表記は、国際音声言語医学会の規定による。 First, a test was conducted on the range of sound that can be produced by the monitor. The test results are shown in Tables 2 and 3. In Table 2 and Table 3, note name notation is in accordance with the regulations of the International Spoken Language Medicine Society.
以上のように、音域の下限（低音側）において音域が広がった人は１５名中５名であり、有効率は約３３．３％であった。 As described above, 5 out of 15 people whose sound range was widened at the lower limit of the sound range (bass side), and the effectiveness rate was about 33.3%.
以上のように、音域の上限（高音側）において音域が広がった人は１５名中１０名であり、有効率は約６６．６％であった。 As described above, 10 persons out of 15 persons whose sound range was widened at the upper limit (high sound side) of the sound range, and the effectiveness rate was about 66.6%.
続いて、各モニターの出しやすい音における発声持続時間について試験を行った。 Subsequently, a test was conducted on the duration of utterance in the sound that each monitor easily produces.
その結果、最長発声持続時間が２０％以上伸びた人は全体の３３．３％であった。 As a result, the number of people whose longest utterance duration increased by 20% or more was 33.3%.
また、モニターからは、以下のような意見も寄せられた。
飲んでいる間、声が出やすい印象を受けた。
仕事（歌手）の翌日の声の疲れが出なくなった。
声が高い方も楽に出せるようになったほか、力強い声が出せるようになり、さらに歌っていて疲れにくくなった。
長い間続いていた声枯れの症状が緩和した。
喉が軽くなった。
ファルセットへの移行がスムーズにできるようになった。
The following comments were also received from the monitor.
While drinking, I got the impression that it was easy to speak.
I was no longer tired of the voice the day after my work (singer).
In addition to being able to speak easily even with high voice, it became possible to produce a strong voice, and singing became less tiring.
The symptoms of voice dying that had continued for a long time were alleviated.
My throat got lighter.
The transition to Falset can be done smoothly.
さらに、上記のモニターとは異なるモニターに、本実施例の発声改善剤を服用してその効果を実感できるまでの時間、具体的には発声可能な音域が広がったと感じるまでの時間を測定した。 Furthermore, the time required to take the utterance improving agent of the present example and feel the effect on a monitor different from the above monitor, specifically, the time required to feel that the sound range that can be uttered was expanded was measured.
以下、具体的に説明する。本試験に係るモニター（５名）は、歌唱を開始する前に、本実施例の発声改善剤を２個、経口により服用した。続いて、喉の状態が良くなったことを自覚するまで安静を維持した。表５に、モニターが、服用後から喉の状態が良くなったことを自覚するまでの時間を示す。さらに、自覚後、モニターがよく歌う曲のうち、比較的音調が高めで歌いにくい曲を歌ってみて、いつもよりスムーズに歌えることをそれぞれ確認した。また、３曲以上歌っても喉が痛くなるか否か、翌朝も通常どおり発声できたか否かを確認した。 This will be specifically described below. The monitors (5 persons) involved in this test took 2 oral utterance improvers of this example orally before starting singing. Subsequently, he was kept resting until he realized that his throat was in good condition. Table 5 shows the time until the monitor realizes that the condition of the throat has improved after taking. In addition, after consciousness, I sang songs that the monitor sings well and is relatively difficult to sing, and confirmed that they can sing more smoothly than usual. In addition, I confirmed whether or not the song hurts even if I sang 3 or more songs, and whether or not I was able to speak normally the next morning.
当該試験の結果、モニターはいずれも、２０〜４０分の間、平均しておよそ３０分程度で効果を実感することができた。また、いずれのモニターも、通常歌いにくかった歌をスムーズに歌うことができた。さらに、３曲以上歌っても喉の痛みは生じず、翌朝も通常どおり発声することができた。 As a result of the test, all the monitors were able to realize the effect in an average of about 30 minutes for 20 to 40 minutes. In addition, all monitors were able to sing songs that were difficult to sing normally. In addition, singing more than three songs did not cause sore throat, and I was able to speak as usual the next morning.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008076905A JP5260996B2 (en) | 2008-03-25 | 2008-03-25 | Voice improvement agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008076905A JP5260996B2 (en) | 2008-03-25 | 2008-03-25 | Voice improvement agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009227625A true JP2009227625A (en) | 2009-10-08 |
| JP5260996B2 JP5260996B2 (en) | 2013-08-14 |
Family
ID=41243441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008076905A Active JP5260996B2 (en) | 2008-03-25 | 2008-03-25 | Voice improvement agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5260996B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013797A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Throat heat clearing granule |
| CN104740400A (en) * | 2015-03-31 | 2015-07-01 | 高绍荣 | Traditional Chinese medicine for treating throat cancer |
| CN105079422A (en) * | 2015-09-16 | 2015-11-25 | 韩志强 | Preparation method of refined compound fritillaria cirrhosa tablet |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07300421A (en) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | Anti-inflammatory agent |
| JP2002193796A (en) * | 2000-12-27 | 2002-07-10 | Ajinomoto Co Inc | Inhibitor to activation of inflammatory factor, usage thereof and new polysulfide derivative usable for the same |
| JP2003252736A (en) * | 2001-12-27 | 2003-09-10 | Earth Chem Corp Ltd | Liquid composition for oral cavity and throat |
| JP2004359595A (en) * | 2003-06-04 | 2004-12-24 | Earth Chem Corp Ltd | Liquid throat-protective composition |
| JP2006008717A (en) * | 2005-05-31 | 2006-01-12 | Yamaha Motor Co Ltd | Interleukin inhibitor |
| JP2007204436A (en) * | 2006-02-02 | 2007-08-16 | Bio Yakuhin Kk | Phonation improving agent and method for improving phonation |
| JP2007238441A (en) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | Composition for body fat reduction containing astaxanthin as active ingredient |
| JP2007527358A (en) * | 2003-12-26 | 2007-09-27 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | A herbal preparation as a brain tonic, containing camellia and sesame |
-
2008
- 2008-03-25 JP JP2008076905A patent/JP5260996B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07300421A (en) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | Anti-inflammatory agent |
| JP2002193796A (en) * | 2000-12-27 | 2002-07-10 | Ajinomoto Co Inc | Inhibitor to activation of inflammatory factor, usage thereof and new polysulfide derivative usable for the same |
| JP2003252736A (en) * | 2001-12-27 | 2003-09-10 | Earth Chem Corp Ltd | Liquid composition for oral cavity and throat |
| JP2004359595A (en) * | 2003-06-04 | 2004-12-24 | Earth Chem Corp Ltd | Liquid throat-protective composition |
| JP2007527358A (en) * | 2003-12-26 | 2007-09-27 | カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ | A herbal preparation as a brain tonic, containing camellia and sesame |
| JP2007238441A (en) * | 2004-12-03 | 2007-09-20 | Fuji Chem Ind Co Ltd | Composition for body fat reduction containing astaxanthin as active ingredient |
| JP2006008717A (en) * | 2005-05-31 | 2006-01-12 | Yamaha Motor Co Ltd | Interleukin inhibitor |
| JP2007204436A (en) * | 2006-02-02 | 2007-08-16 | Bio Yakuhin Kk | Phonation improving agent and method for improving phonation |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104013797A (en) * | 2014-06-20 | 2014-09-03 | 苏州法莫生物技术有限公司 | Throat heat clearing granule |
| CN104740400A (en) * | 2015-03-31 | 2015-07-01 | 高绍荣 | Traditional Chinese medicine for treating throat cancer |
| CN105079422A (en) * | 2015-09-16 | 2015-11-25 | 韩志强 | Preparation method of refined compound fritillaria cirrhosa tablet |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5260996B2 (en) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Packer | Protective role of vitamin E in biological systems | |
| EP2219477B1 (en) | Composition for regulating lipid metabolism | |
| CN104010634B (en) | Composition for treating neurological conditions | |
| JP6629595B2 (en) | Synergistic dietary supplement composition for enhancing physical performance and energy levels | |
| WO2002032234A1 (en) | Anti-stress composition designed to be mainly incorporated in nutritional carriers | |
| CN102093939A (en) | Nutrition-enhanced health-care wine prepared from plant containing natural biological antioxidant | |
| Singh et al. | Role of nutraceuticals in cognition during aging and related disorders | |
| Jacques | Ideophones in Japhug (Rgyalrong) | |
| JP5260996B2 (en) | Voice improvement agent | |
| da Rocha Lapa et al. | Vasorelaxant and hypotensive effects of the extract and the isolated flavonoid rutin obtained from Polygala paniculata L. | |
| BRPI0716108B8 (en) | composition, use of a composition, and, method for making a composition | |
| WO2012049222A2 (en) | Novel omega-3 and omega-6 fatty acid compositions and uses thereof | |
| Muid et al. | Optimal antioxidant activity with moderate concentrations of Tocotrienol rich fraction (TRF) in in vitro assays. | |
| Blaylock | Neurodegeneration and aging of the central nervous system: Prevention and treatment by phytochemicals and metabolic nutrients | |
| Ikemura et al. | Protective effects of nobiletin on hypertension and cerebral thrombosis in stroke-prone spontaneously hypertensive rats (SHRSP) | |
| CN105495153B (en) | A kind of antioxidant health-care product containing phycocyanin and ginkgo biloba p.e | |
| JP2009501169A (en) | Ginkgo biloba extract | |
| Shahzad et al. | Spirulina platensis (Blue-green algae): A miracle from sea combats the oxidative stress and improves behavioral deficits in an animal model of Schizophrenia | |
| Ostojic | Molecular Nutrition and Mitochondria: Metabolic Deficits, Whole-Diet Interventions, and Targeted Nutraceuticals | |
| EP1414315B9 (en) | Complex antioxidant preparation | |
| Tenchov et al. | Aging hallmarks and anti-aging strategies: a landscape of research advancement | |
| US20060270732A1 (en) | Antioxidant supplement compostion and method of use | |
| CN111743936A (en) | Functional hemp chewing gum for improving memory and reducing pressure and preparation method thereof | |
| EP3229818B1 (en) | Use of a particular extract of propolis for combating the side effects of chemotherapy | |
| DE102006038793A1 (en) | Food supplement, useful e.g. to prevent disease and malnutrition and to optimize the nutrition of the body, comprises a combination of grapes kernel oil, lycopene-containing tomatoes extract and bilberry extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130416 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130426 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160502 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5260996 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |